Acinetobacter baumannii is a pathogen of increasing concern, commonly causing outbreaks
in the hospital environment. Of particular concern, A. baumannii strains exhibiting resistance …

Acinetobacter baumannii is an important op-portunistic pathogen that is rapidly evolving
toward multidrug resistance (MDR) and is involved in various nosocomial infections …

Tigecycline seems to be a promising agent for treatment of resistant Acinetobacter
baumannii infections, however approved criteria for susceptibility testing are still lacking …

Sir, Acinetobacter baumannii is a significant nosocomial pathogen, in particular in ICU
patients. Their multidrug resistance, propensity for clonal spread and involvement in hospital …

Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter
baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In …

Acinetobacter baumannii is widely distributed in nature and in hospital settings and is a
common pathogen causing various infectious diseases. Currently, the drug resistance rate …

We performed susceptibility testing using the microdilution method to determine the in-vitro
activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 …

Acinetobacter baumannii has become a serious concern in clinical practice owing to its
multiple resistance to antimicrobial agents. Tigecycline and colistin may be used as …

What is known and objective Acinetobacter baumannii is one of the most important
nosocomial pathogens with the ability to cause infections such as meningitis, pneumonia …

Abstract Objectives Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our
hospital and worldwide, raising the necessity of finding effective therapies. We aimed to …